Clinical Trials Browser

Terminated × OTHER × enzalutamide × Clear all

NCT01885949 2026-02-24

Tivozanib + Enzalutamide in Adv Prostate Cancer

Phase 2 Terminated

5 enrolled 7 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05037500 2025-11-12

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT03300505 2025-05-13

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

9 enrolled 14 charts

Prostatic Neoplasms

NCT03177187 2024-09-26

ACE

Phase 1/2 Terminated

Metastatic Castration Resistant Prostate Cancer

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 Terminated

Prostatic Neoplasms, Patient Preference

NCT02640534 2023-06-27

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Phase 2 Terminated

Prostatic Neoplasms

NCT04142060 2022-10-28

ARIANNA

Phase 2 Terminated

Breast Neoplasms

NCT02457910 2022-08-22

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Phase 1/2 Terminated

30 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02508636 2021-10-12

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

Phase 2 Terminated

11 enrolled 17 charts

Prostatic Neoplasms

NCT02489123 2021-08-10

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Terminated

8 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Phase 1 Terminated

Prostate Adenocarcinoma

NCT02685267 2021-04-09

Doce/Enza

Phase 2 Terminated

9 enrolled 11 charts

Prostatic Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Phase 2 Terminated

1 enrolled 7 charts

Prostatic Neoplasms

NCT02500901 2019-10-21

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Phase 1 Terminated

2 enrolled 8 charts

Prostatic Neoplasms

NCT02491411 2018-07-12

DEXTER

Phase NA Terminated

5 enrolled 5 charts

Prostatic Neoplasms